Psychopharmacologic Treatment of Eating Disorders: Emerging Findings

摘要: Psychopharmacologic treatment is playing a greater role in the management of patients with eating disorders. In this paper, we review randomized, placebo-controlled trials (RCTs) conducted anorexia nervosa (AN), bulimia (BN), binge disorder (BED), and other disorders over past 3 years. Fluoxetine remains only medication approved for an disorder, that being BN. RCTs antipsychotics AN have had mixed results; agent some evidence efficacy olanzapine. One study suggests dronabinol may induce weight gain AN. Preliminary studies suggest lack alprazolam, dehydroepiandrosterone, or physiologic estrogen replacement AN; erythromycin BN; opioid antagonist ALKS-33 BED. BED obesity overweight, bupropion cause mild loss without seizures, chromium improve glucose regulation. Also BED, three stimulant prodrug lisdexamfetamine reduce episodes, another RCT intranasal naloxone decrease time spent eating. There disconnection between size as public health problem pharmacotherapy research these conditions.